Marco Meglio

The duo from Vanderbilt University discussed the lack of awareness for functional seizures, their differences in treatment, and what needs to change about their current management.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed a recently initiated study that will look at the FDA-approved cancer drug lenalidomide for the treatment of Alzheimer disease.

Researchers observed statistically significant improvements of the EDSS score along with a majority of patients showing no new enlarging or gadolinium-enhancing MRI lesions.

Using the largest existing cEEG data set, researchers identified seizure chronotypes at multiple timescales, noting that circadian and multidien seizure cycles are equally strong and highly prevalent.

ACI-12589 aims to become the world’s first diagnostic tool for assessing brain alpha-synuclein pathology in patients with Parkinson disease.

AMT-130 is uniQure’s first clinical program focusing on the central nervous system incorporating its proprietary miQURE silencing technology platform.

The director of the Dartmouth Epilepsy Program and chairwoman of AES 2020 discussed some of the major topics from the previously completed annual meeting and where epilepsy research is trending.

The proportion of patients treated with prednisone and the prednisone dose tended to be lower in the rapid-tapering group at 15 months compared to slow-tapering arm.

The Genio system offers bilateral stimulation of the hypoglossal nerve branches, which may lead to potentially greater airway opening for patients with obstructive sleep apnea.

The duo from Vanderbilt University shared background on their recently published study that found novel associations between functional seizures, cerebrovascular disease, and other psychiatric disorders.

The eXciteOSA device is a daytime therapy that uniquely targets the root cause of snoring and mild obstructive sleep apnea by using electrical currents to stimulate and improve muscle function in the mouth and tongue.

Lisa Belter, MPH, director of research analytics at Cure SMA, discussed a recently published study on the rising costs of living for patients with spinal muscular atrophy.

The company also plans on submitting an application to a PDAC contractor for the mmRNA appliance to be added to the Center for Medicare and Medicaid Services’ list of approved sleep apnea appliances.

The director of the Massachusetts General Hospital ALS Care Center discussed the greatest needs in ALS research and why focusing on genetics can play a big role into understanding the disease course.

Study data showed that 43% of patients with obstructive sleep apnea were referred to sleep specialist physicians for ongoing management by a primary care provider.

The RAISE trial will examine the proportion of patients with refractory status epilepticus who experience status cessation within 30 minutes of initiation of intravenous ganaxolone.

Observation of pain freedom at 30 minutes was more accurate than the observation of relief at 30 minutes in predicting pain freedom at 2 hours.

Earlier AD diagnosis with the AlzoSure assay could potentially make it feasible to initiate disease-modifying therapies much earlier in the disease process.

Gocovri is now the only therapy to be approved in the US to treat both off episodes and dyskinesia in patients with Parkinson disease.

Barbara Karp, MD, and Sharon Meropol, MD, discuss the recently launched NeuroCOVID databank from the NIH, which will track neurologic symptoms associated with COVID-19.

RACE, G-FAST, and CG-FAST were among the best performing prehospital stroke scales out of 8 scales tested and approached the performance of the clinician-assessed NIHSS.

Treatment with low-dose protocol of rituximab is sufficient to maintain suppression of inflammatory disease activity in most patients with relapsing-remitting multiple sclerosis.

The basis of the approval for peginterferon beta-1a was from a phase 1 crossover study that showed the drug’s bioequivalence to subcutaneous injection.

The researchers noted that the recovery model can use all available serially assessed data in a flexible way, creating a prediction at any desired moment poststroke, stand-alone, or linked with an electronic health record system.

Clinically relevant scores of 32 and 44 on the Fugl-Meyer Motor Score were documented in 2 patients who received NSI-566.

Specific health-related quality of life measures in physical activities, well-being, cognition, and social activities were improved among those who underwent the laser ablation procedure.

Relapse, followed by medication history and age, was among the highest exclusion rates for MS trials across different disease-modifying therapies.

Creative Medical Technology’s ImmCelz contrasts other stem cell-based approaches by utilizing stem cells outside of the body to reprogram the patient’s own immune cells.

The director of the Massachusetts General Hospital ALS Care Center sat down to discuss ‘The Data is Here’ campaign from Answer ALS, the world’s largest open-sourced ALS data portal.

Preclinical studies have shown that the homeoprotein hEN1 is essential for the survival and maintenance of spinal cord alpha motor neurons that innervates muscles throughout the body.